Endocrine signaling research
CJC-1295 with DAC
Lyophilized endocrine-signaling research peptide for systems review
CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Research context
CJC-1295 with DAC research profile
CJC-1295 with DAC is a longer-acting GHRH analog designed to extend exposure through drug-affinity-complex chemistry and albumin binding. Research examines pharmacokinetics, prolonged GH and IGF-1 marker changes, pituitary signaling, and how sustained activity differs from shorter GHRH analogs. It is distinct from CJC-1295 No DAC, which is used for shorter pulse-pattern comparisons, and from ipamorelin or GHRP compounds, which signal through the ghrelin receptor. This version is most relevant when half-life extension is central to the study design. Published pharmacology for named investigational material does not independently verify the sequence, purity, or performance of a catalog batch.
Proposed mechanism
A GHRH analog containing a drug-affinity-complex group designed to form a covalent bond with serum albumin. Albumin binding reduces clearance and prolongs GHRH-receptor stimulation, increasing GH secretion and downstream IGF-1.
Effects reported in studies
- Healthy-adult studies reported dose-dependent increases in GH lasting several days and increases in IGF-1 lasting approximately one to two weeks after studied exposures.
- Repeated exposure in pharmacology studies produced sustained elevation of GH and IGF-1 without eliminating pulsatile secretion.
- Reported observations included injection-site reactions and endocrine changes expected from prolonged GH-axis stimulation.
Common research endpoints
Albumin binding, half-life, GHRH receptor activity, GH pulse pattern, integrated GH exposure, IGF-1, glucose, insulin, binding proteins, pharmacokinetics, and adverse events.
Evidence and limitations
Controlled human pharmacology exists for the original investigational CJC-1295 with DAC. Product sequence and DAC chemistry must match before those data are considered relevant.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
GH axis Research peptide
CJC-1295 No DAC
CJC-1295 No DAC is a short-acting GHRH analog studied as a pituitary GH-axis signaling reference.
- Form
- Lyophilized powder
- Amount
- 5 mg
Price range: 34.99 $ through 259.99 $ Select options This product has multiple variants. The options may be chosen on the product page